Collaboration And License Agreements (Tables)

12 Months Ended

Dec. 31, 2011

Collaboration And License Agreements [Abstract]

Schedule Of Revenues Recognized Under The Agreements

	Years ended December 31,
	2011		2010		2009
Millennium	$	27,914	$	16,040	$	1,690
Genentech		5,302		82,819		41,594
Pfizer		4,500		0		0
Agensys		3,957		2,256		4,029
Abbott		3,721		219		0
GSK		3,037		3,013		0
Other		3,106		3,123		4,652
Total	$	51,537	$	107,470	$	51,965

Summary Of Research And Development Expenses Incurred And Funding Provided To Agensys

	Years ended December 31,
	2011		2010		2009
Research and development expense using contractual rates	$	6,404	$	4,654	$	4,824
Co-development funding due to Agensys		6,844		360		764
Total	$	13,248	$	5,014	$	5,588